Associate Company Spotlight: Celsion

HudsonAlpha Associate Company “Opens Doors” To Help Early Stage Biotech Companies

Celsion Logo 2

Celsion may be new to the HudsonAlpha campus, but the publicly owned biopharmaceutical company is already expanding its business.

“One of our focuses is to become a research partner for early stage biotech companies that may not have all of the capabilities that we have,” said Jason Fewell, PhD, Celsion’s vice president for preclinical research.

Headquartered in Lawrenceville, N.J., Celsion joined the HudsonAlpha campus in 2014 after acquiring long-time HudsonAlpha associate company Egen, Inc. The goal of the acquisition was to create a fully integrated, oncology-focused research and development company with a multi-phase clinical pipeline, platform technologies for the discovery of novel immunotherapies and other anti-cancer DNA/RNA therapies, and expertise from bench to bedside. The company’s discovery and preclinical operations, as well as its analytical services and laboratory functions, are now based in Huntsville, Ala.

Since 2014, Celsion’s relationship with HudsonAlpha and the associate companies located on the Institute’s campus continues to grow through its expansion into preclinical contract research services, which was announced late last year. The company’s broad-based technology and product platform in cancer therapeutics spans from early stage drug candidates to Phase III registration products in multiple disease areas of high unmet clinical need. Its infrastructure, supported by scientific expertise in product development from bench to bedside, is positioned to support this new investment and expansion into the complimentary businesses of contract research services.

The expansion of research services brings new possibilities to both Celsion and the associate companies on HudsonAlpha’s campus.

“We have benefitted from being able to build upon infrastructure and research that was carried out because we were developing our own drugs,” said Khursheed Anwer, PhD, chief scientific officer and executive vice president of Celsion. “We are now opening the door of our house to others in order to benefit from services that were useful for us.”